Developer docs
API playgroundTry for free, no card

Search company profiles

PreventionGenetics

Full company profile

uuid000cpb8

Namestring
PreventionGenetics
Legal namestring
PreventionGenetics LLC
Websiteurl
preventiongenetics.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

PreventionGenetics is a clinical genetic testing laboratory founded in 2004 by Dr. James Weber and headquartered at 3800 S. Business Park Ave., Marshfield, Wisconsin. The company operates a CAP-accredited, CLIA-certified laboratory and offers three core testing modalities: PGnome® whole genome sequencing, PGxome® whole exome sequencing, and PGmax™ targeted gene panels, covering more than 6,000 clinically relevant genes. The company is a wholly owned subsidiary of Exact Sciences Corporation (NASDAQ: EXAS).

The company serves healthcare professionals — primarily physicians and genetic counselors — who order tests through the myPrevent online portal. Sample collection kits are shipped directly to patients' homes, and expert-reviewed genetic reports are returned to the ordering clinician for use in patient diagnosis and care planning, particularly for rare disease and genetic disorder cases. The company supports more than 240 clinical trials or research projects and processes 100,000+ cases annually with greater than 99% CAP proficiency testing scores.

Revenue is generated through clinical genetic testing services billed primarily through insurance, with PreventionGenetics maintaining in-network provider status with major commercial payers (Aetna, Anthem, Cigna, Humana, UnitedHealthcare) and enrollment in all 50 state Medicaid plans. The company is investing in AI-enabled variant curation through a partnership with the AWS Generative AI Innovation Center, using Amazon Bedrock large language models and Amazon Textract to automate literature search and evidence extraction, reportedly reducing research times for variant analysis by 30%.

Short descriptiontext

PreventionGenetics is a CAP-accredited, CLIA-certified clinical genetic testing laboratory in Marshfield, Wisconsin, serving healthcare professionals with whole genome, whole exome, and targeted gene panel tests across 6,000+ clinically relevant genes. It operates as a wholly owned subsidiary of Exact Sciences Corporation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMarshfield, United States
HQ citystring
Marshfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genetic testing, whole genome sequencing, whole exome sequencing, targeted gene panels, diagnostic laboratory services
Industry5 codes
1Genetic & Prenatal Testing Laboratories
CodeHLAFAMAHPrimaryYes
2Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
CodeHLAAALADPrimaryNo
3Molecular Diagnostics & Genomics Laboratories
CodeHLAFAMAEPrimaryNo
4Genetic, Cytogenetic & Prenatal Screening IVD
CodeHLAHAAAIPrimaryNo
5Genomics & Molecular Diagnostics (Trial Support)
CodeHLAGAEADPrimaryNo
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Genetic Testing / Diagnostic Laboratory Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Genetic Testing Services
TypeOne Time License
Description

PreventionGenetics generates revenue through providing genetic testing services to healthcare professionals. Tests are ordered online through myPrevent platform, sample collection kits are shipped to patients, and expert-reviewed genetic reports are delivered to clinicians for patient care planning. The company is an in-network provider with major health insurers including Aetna, Anthem, Cigna, Humana, and UnitedHealthcare, and is enrolled in all 50 state Medicaid plans.

preventiongenetics.com:443
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1PGnome®
Description

Whole genome sequencing (WGS) tests for comprehensive genetic analysis

preventiongenetics.com:443
+2 more records
Core offering1 text field

PreventionGenetics operates a CAP-accredited and CLIA-certified clinical genetic testing laboratory providing next-generation sequencing-based diagnostic services to healthcare professionals. The company offers whole genome sequencing (PGnome®), whole exome sequencing (PGxome®), and targeted gene panels (PGmax™) covering 6,000+ clinically relevant genes, with orders placed online through the myPrevent portal, sample kits shipped directly to patients, and expert-reviewed genetic reports returned to clinicians for care planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 30% reduction in research times through AI-powered variant curation (via Amazon Bedrock partnership)
Product overview1 text field

PreventionGenetics is a genetic testing laboratory offering a multi-tiered portfolio of products. The core offerings include three main testing modalities: PGnome® Tests (whole genome sequencing/WGS), PGxome® Tests (whole exome sequencing/WES), and PGmax™ Panels (targeted gene panels). These products are supported by a comprehensive Test Catalog that enables healthcare professionals to explore testing options for nearly 6,000 clinically relevant genes. The company also provides an online ordering platform called myPrevent for managing orders. All tests are performed in PreventionGenetics' CAP-accredited and CLIA-certified laboratory in Marshfield, Wisconsin, and the company serves as a wholly owned subsidiary of Exact Sciences Corp.

Product and service5 records
1PGnome® Tests
CategoryClinical Genetic Testing - Whole Genome Sequencing
Description

Whole genome sequencing (WGS) tests that analyze the complete DNA sequence of an individual's genome, enabling comprehensive detection of genetic variants across all clinically relevant genes. Performed in the CAP-accredited and CLIA-certified Marshfield, Wisconsin laboratory for healthcare professionals ordering diagnostic tests.

2PGxome® Tests
CategoryClinical Genetic Testing - Whole Exome Sequencing
Description

Whole exome sequencing (WES) tests that sequence the protein-coding regions of the genome, focusing on variants most likely to affect protein function and disease phenotype. Targeted at healthcare professionals diagnosing genetic disorders in patients.

3PGmax™ Panels
CategoryClinical Genetic Testing - Targeted Gene Panels
Description

Targeted gene panel tests that analyze specific sets of genes associated with particular conditions or clinical indications, offering a more focused and cost-efficient alternative to whole genome or exome sequencing. Used by healthcare professionals for condition-specific genetic analysis.

4Test Catalog
CategoryTest Catalog / Reference Resource
Description

Comprehensive searchable catalog of genetic tests covering nearly all clinically relevant genes, enabling healthcare professionals to discover and select appropriate testing options for their patients. Supports ordering selection across the PGnome®, PGxome®, and PGmax™ test families.

5myPrevent Online Ordering Platform
CategoryClinical Workflow Platform
Description

Online ordering and order management platform that allows healthcare professionals to place genetic testing orders and manage all orders in a single dashboard, streamlining the testing workflow from order through sample shipment to result delivery.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1AWS Generative AI Innovation Center
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-29
Description

PreventionGenetics collaborated with the AWS Generative AI Innovation Center to build a Variant Curation Accelerator proof of concept in six weeks. The solution uses Amazon Bedrock with large language models to search relevant papers, extract findings via Amazon Textract, and present results for human review, achieving a 30 percent reduction in research times for variant analysis.

aws.amazon.com
2Amazon
Strategic tierCoreTypeTechnology or Integration
Description

PreventionGenetics utilizes Amazon Bedrock for AI-powered variant curation, enabling automated genetic variant analysis using large language models to accelerate diagnostic insights for patients with rare diseases.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PreventionGenetics

Clinical Genetic Testing / Diagnostic Laboratory Servicespreventiongenetics.com

PreventionGenetics is a CAP-accredited, CLIA-certified clinical genetic testing laboratory in Marshfield, Wisconsin, serving healthcare professionals with whole genome, whole exome, and targeted gene panel tests across 6,000+ clinically relevant genes. It operates as a wholly owned subsidiary of Exact Sciences Corporation.

What PreventionGenetics does

PreventionGenetics is a clinical genetic testing laboratory founded in 2004 by Dr. James Weber and headquartered at 3800 S. Business Park Ave., Marshfield, Wisconsin. The company operates a CAP-accredited, CLIA-certified laboratory and offers three core testing modalities: PGnome® whole genome sequencing, PGxome® whole exome sequencing, and PGmax™ targeted gene panels, covering more than 6,000 clinically relevant genes. The company is a wholly owned subsidiary of Exact Sciences Corporation (NASDAQ: EXAS).

The company serves healthcare professionals — primarily physicians and genetic counselors — who order tests through the myPrevent online portal. Sample collection kits are shipped directly to patients' homes, and expert-reviewed genetic reports are returned to the ordering clinician for use in patient diagnosis and care planning, particularly for rare disease and genetic disorder cases. The company supports more than 240 clinical trials or research projects and processes 100,000+ cases annually with greater than 99% CAP proficiency testing scores.

Revenue is generated through clinical genetic testing services billed primarily through insurance, with PreventionGenetics maintaining in-network provider status with major commercial payers (Aetna, Anthem, Cigna, Humana, UnitedHealthcare) and enrollment in all 50 state Medicaid plans. The company is investing in AI-enabled variant curation through a partnership with the AWS Generative AI Innovation Center, using Amazon Bedrock large language models and Amazon Textract to automate literature search and evidence extraction, reportedly reducing research times for variant analysis by 30%.

PreventionGenetics firmographics

Firmographics
Name
PreventionGenetics
Legal name
PreventionGenetics LLC
Website
https://preventiongenetics.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
PreventionGenetics is a CAP-accredited, CLIA-certified clinical genetic testing laboratory in Marshfield, Wisconsin, serving healthcare professionals with whole genome, whole exome, and targeted gene panel tests across 6,000+ clinically relevant genes. It operates as a wholly owned subsidiary of Exact Sciences Corporation.
Ownership category
akta.pro rank

PreventionGenetics industry classification

Industry
Product category
Clinical Genetic Testing / Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Genetic & Prenatal Testing Laboratories (HLAFAMAH)
akta.pro secondary industries
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

  • Clinical genetic testing
  • Whole genome sequencing
  • Whole exome sequencing
  • Targeted gene panels
  • Diagnostic laboratory services

Where PreventionGenetics is headquartered

Location

Headquarters

HQ city
Marshfield
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PreventionGenetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Clinical Genetic Testing Services: PreventionGenetics generates revenue through providing genetic testing services to healthcare professionals. Tests are ordered online through myPrevent platform, sample collection kits are shipped to patients, and expert-reviewed genetic reports are delivered to clinicians for patient care planning. The company is an in-network provider with major health insurers including Aetna, Anthem, Cigna, Humana, and UnitedHealthcare, and is enrolled in all 50 state Medicaid plans.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

PreventionGenetics product offering

Product offering

Core offering

PreventionGenetics operates a CAP-accredited and CLIA-certified clinical genetic testing laboratory providing next-generation sequencing-based diagnostic services to healthcare professionals. The company offers whole genome sequencing (PGnome®), whole exome sequencing (PGxome®), and targeted gene panels (PGmax™) covering 6,000+ clinically relevant genes, with orders placed online through the myPrevent portal, sample kits shipped directly to patients, and expert-reviewed genetic reports returned to clinicians for care planning.

Product overview

PreventionGenetics is a genetic testing laboratory offering a multi-tiered portfolio of products. The core offerings include three main testing modalities: PGnome® Tests (whole genome sequencing/WGS), PGxome® Tests (whole exome sequencing/WES), and PGmax™ Panels (targeted gene panels). These products are supported by a comprehensive Test Catalog that enables healthcare professionals to explore testing options for nearly 6,000 clinically relevant genes. The company also provides an online ordering platform called myPrevent for managing orders. All tests are performed in PreventionGenetics' CAP-accredited and CLIA-certified laboratory in Marshfield, Wisconsin, and the company serves as a wholly owned subsidiary of Exact Sciences Corp.

Differentiator

Problem solved

Functional benefit

Brands

  • PGnome®: Whole genome sequencing (WGS) tests for comprehensive genetic analysis
  • PGxome®
  • PGmax™

Products and services

  • PGnome® Tests Whole genome sequencing (WGS) tests that analyze the complete DNA sequence of an individual's genome, enabling comprehensive detection of genetic variants across all clinically relevant genes. Performed in the CAP-accredited and CLIA-certified Marshfield, Wisconsin laboratory for healthcare professionals ordering diagnostic tests.
  • PGxome® Tests Whole exome sequencing (WES) tests that sequence the protein-coding regions of the genome, focusing on variants most likely to affect protein function and disease phenotype. Targeted at healthcare professionals diagnosing genetic disorders in patients.
  • PGmax™ Panels Targeted gene panel tests that analyze specific sets of genes associated with particular conditions or clinical indications, offering a more focused and cost-efficient alternative to whole genome or exome sequencing. Used by healthcare professionals for condition-specific genetic analysis.
  • Test Catalog Comprehensive searchable catalog of genetic tests covering nearly all clinically relevant genes, enabling healthcare professionals to discover and select appropriate testing options for their patients. Supports ordering selection across the PGnome®, PGxome®, and PGmax™ test families.
  • myPrevent Online Ordering Platform Online ordering and order management platform that allows healthcare professionals to place genetic testing orders and manage all orders in a single dashboard, streamlining the testing workflow from order through sample shipment to result delivery.

Quantifiable outcome

  • 30% reduction in research times through AI-powered variant curation (via Amazon Bedrock partnership)

Companies that use PreventionGenetics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

PreventionGenetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PreventionGenetics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AWS Generative AI Innovation CentercoreTechnology or Integration · 29 April 2026PreventionGenetics collaborated with the AWS Generative AI Innovation Center to build a Variant Curation Accelerator proof of concept in six weeks. The solution uses Amazon Bedrock with large language models to search relevant papers, extract findings via Amazon Textract, and present results for human review, achieving a 30 percent reduction in research times for variant analysis.
  • AmazoncoreTechnology or IntegrationPreventionGenetics utilizes Amazon Bedrock for AI-powered variant curation, enabling automated genetic variant analysis using large language models to accelerate diagnostic insights for patients with rare diseases.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

PreventionGenetics competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

PreventionGenetics social profiles

Digital presence

PreventionGenetics compliance and trust

Trust signal

Compliance3 records

PreventionGenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PreventionGenetics leadership team

Management profile

Number of profiles

Profiles1 record

PreventionGenetics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PreventionGenetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PreventionGenetics

What does PreventionGenetics do?

PreventionGenetics operates a CAP-accredited and CLIA-certified clinical genetic testing laboratory providing next-generation sequencing-based diagnostic services to healthcare professionals. The company offers whole genome sequencing (PGnome®), whole exome sequencing (PGxome®), and targeted gene panels (PGmax™) covering 6,000+ clinically relevant genes, with orders placed online through the myPrevent portal, sample kits shipped directly to patients, and expert-reviewed genetic reports returned to clinicians for care planning.

Is PreventionGenetics a public or private company?

PreventionGenetics is a private company. It is classified as corporate owned and is currently operating.

When was PreventionGenetics founded?

PreventionGenetics was founded in 2004. It employs 101 to 250 people.

Where is PreventionGenetics based?

PreventionGenetics is headquartered in Marshfield, United States, in the North America region.

How does PreventionGenetics make money?

One revenue line is on record: clinical Genetic Testing Services.

Does PreventionGenetics have an API?

No public API is recorded for PreventionGenetics.

What industry is PreventionGenetics in?

PreventionGenetics's product category is Clinical Genetic Testing / Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PreventiongeneticsSponsored genetic testing programsPreventionGenetics has partnered with several biopharmaceutical companies to launch sponsored genetic testing programs aimed at providing no-cost genetic testing and counseling for various conditions, including sensorineural hearing loss, hereditary transthyretin amyloidosis, and amyotrophic lateral sclerosis. These programs aim to improve early diagnosis and intervention for patients with genetic conditions across multiple regions, including the U.S., Canada, Brazil, and Mexico.GlobeNewswireRelationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and MoreThe relationship genetic tests market is projected to grow from $3.16 billion in 2023 to $3.87 billion in 2024, a 22.4% CAGR, and to $8.81 billion by 2028 at a 22.8% CAGR. Growth is driven by personalized medicine adoption, with AlphaBiolabs launching a DNA test in October 2023 and Exact Sciences acquiring PreventionGenetics in January 2022.ExactsciencesWhat Exactly Is Genetic Testing… And Could It Change the Future of Medicine?A Katie Couric series segment features Dr. Robert Steiner, Chief Medical Officer at PreventionGenetics, explaining how DNA sequencing tests can diagnose rare conditions, predict hereditary cancers, and guide treatment. He notes 99.9% accuracy on positive results, inconclusive variants, and ethical limits on trait selection. Steiner envisions routine comprehensive testing for all patients.PR NewswireGlobal Genetic Testing Market Analysis Report 2022: A $22.91 Billion Market by 2026 - Long-term Forecast to 2031The global genetic testing market is forecast to grow from $13.72 billion in 2021 to $22.91 billion in 2026, representing a compound annual growth rate of 12%, driven by the rising prevalence of genetic disorders including 9.4% of pediatric patients and 13.17 million patients with unique genetic disorders in the US. In January 2022, Exact Sciences acquired Prevention Genetics for $190 million to expand hereditary cancer testing services. Major players in the market include Illumina Inc., Thermo Fisher Scientific, Roche, and Quest Diagnostics, with North America being the largest region and Asia Pacific expected to be the fastest-growing region.HuntingtonsdiseasenewsIntroducing a New Genetic Testing Option for Huntington’s DiseaseB.J. Viau has launched HD Genetics, a new platform offering decentralized genetic counseling and testing for Huntington’s disease via telehealth and mailed saliva kits. The service partners with Prevention Genetics for laboratory analysis and Wes Solem for counseling, currently operating in 14 U.S. states with plans to expand nationwide by year-end.PR NewswirePreventionGenetics Receives FDA Approval for its Companion Diagnostic Genetic Test as a Class II Medical DevicePreventionGenetics, a subsidiary of Exact Sciences Corp., received FDA marketing authorization for its POMC/PCSK1/LEPR companion diagnostic genetic test as a Class II medical device. Developed in collaboration with Rhythm Pharmaceuticals, this is the first FDA-authorized molecular companion diagnostic for IMCIVREE, a therapy for monogenic obesity. The approval enables patients to be matched with targeted therapy by confirming specific genetic variants associated with severe obesity.BioSpaceExact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More PatientsExact Sciences Corp. announced the acquisition of genetic testing laboratory PreventionGenetics for $190 million in cash and stock to expand its capabilities into hereditary cancer testing. The transaction allows Exact Sciences to leverage PreventionGenetics' sequencing technology and clinical expertise to complement its existing cancer diagnostics portfolio, such as Cologuard and Oncotype DX. This strategic move aims to accelerate the availability of germline risk testing for patients across the U.S. and globally.ExactsciencesExact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More PatientsExact Sciences Corp. announced on January 9, 2022 that it has acquired PreventionGenetics, a CLIA-certified, CAP-accredited genetic testing laboratory in Marshfield, Wisconsin, to enter hereditary cancer testing. The $190 million deal is split 50% in Exact Sciences stock and 50% cash. PreventionGenetics expects roughly $36 million in 2021 revenue and $3 million in adjusted EBITDA.PR NewswirePreventionGenetics selected to join Concert Genetics' Preferred Laboratory NetworkPreventionGenetics has joined Concert Genetics' Preferred Laboratory Network, a platform designed to bring transparency to genetic testing pricing and streamline administrative coordination between health plans and laboratories. The network addresses widespread coding variability, high denial rates, and the administrative burden involved in insurance claims processing for genetic testing. PreventionGenetics states this membership furthers its mission of offering transparent pricing and building trusted relationships with health plans to ensure high-quality testing at fair costs.PR NewswireDr. James Weber, PhD, Receives Wisconsin Biohealth Business Achievement Award.Dr. James Weber, President and Founder of PreventionGenetics, received the 2020 Wisconsin Biohealth Business Achievement Award, which recognizes leaders in the biohealth and life science industry in Wisconsin. Founded in 2004, PreventionGenetics has grown into a CLIA and ISO 15189:2012 accredited laboratory providing clinical genetic testing services to patients worldwide. The company recently released its first whole genome sequencing test, PGnome, marking a significant milestone in its offerings.